Skip to main content
. 2023 Jul 28;24(15):12106. doi: 10.3390/ijms241512106

Table 4.

Summary of trials of T-PLL with allo-HSCT ***.

Reference n CR (%) at allo-HSCT PR (%) at allo-HSCT OS Relapse Rate
[68] 37 60% 27% 4-year OS: 42% 38% at 4 years
[69] 27 51% 37% 3-year OS: 36% 47% at 3 years
[70] 11 81% 9% 4-year OS: 56% 21% at 4 years
[71] 20 30% 5% 3-year OS: 39.8% 69.6% at 3 years
[66] 266 56% 30% 4-year OS: 30% 41.9% at 4 years

*** Adapted from [66].